NASDAQ:IOBT IO Biotech (IOBT) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free IOBT Stock Alerts $1.23 -0.02 (-1.60%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.19▼$1.2950-Day Range$1.18▼$1.7152-Week Range$0.82▼$2.22Volume153,047 shsAverage Volume126,128 shsMarket Capitalization$81.23 millionP/E RatioN/ADividend YieldN/APrice Target$9.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get IO Biotech alerts: Email Address IO Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside684.0% Upside$9.67 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$803,747 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.27) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.70 out of 5 starsMedical Sector616th out of 905 stocksPharmaceutical Preparations Industry288th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIO Biotech has only been the subject of 1 research reports in the past 90 days.Read more about IO Biotech's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.09% of the float of IO Biotech has been sold short.Short Interest Ratio / Days to CoverIO Biotech has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IO Biotech has recently increased by 1.77%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIO Biotech does not currently pay a dividend.Dividend GrowthIO Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IOBT. Previous Next 1.1 News and Social Media Coverage Search Interest2 people have searched for IOBT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added IO Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IO Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $803,747.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of IO Biotech is held by insiders.Percentage Held by Institutions54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IO Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IO Biotech are expected to decrease in the coming year, from ($1.27) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IO Biotech is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IO Biotech is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIO Biotech has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about IO Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About IO Biotech Stock (NASDAQ:IOBT)IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Read More IOBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOBT Stock News HeadlinesMay 15, 2024 | insidertrades.comInsider Selling: IO Biotech, Inc. (NASDAQ:IOBT) Major Shareholder Sells 658,809 Shares of StockMay 27, 2024 | finance.yahoo.comWill IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?May 23, 2024 | globenewswire.comIO Biotech to Present at Jefferies Global Healthcare ConferenceMay 15, 2024 | markets.businessinsider.comOptimistic Buy Rating for IO Biotech Amidst Promising Clinical Trial Progress and Accelerated PFS Data TimelineMay 14, 2024 | investorplace.comIOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024May 14, 2024 | globenewswire.comIO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsApril 24, 2024 | globenewswire.comIO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 17, 2024 | msn.comIO Biotech (IOBT) Price Target Decreased by 11.11% to 8.16April 15, 2024 | globenewswire.comIO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessApril 11, 2024 | investing.comIO Biotech presents cancer vaccine data at AACRApril 9, 2024 | globenewswire.comIO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103April 5, 2024 | globenewswire.comIO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerMarch 7, 2024 | finance.yahoo.comIO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical TrialsMarch 6, 2024 | markets.businessinsider.comBuy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock PositionMarch 6, 2024 | morningstar.comIO Biotech Inc IOBTMarch 6, 2024 | msn.comIO Biotech GAAP EPS of -$0.40 misses by $0.02March 6, 2024 | globenewswire.comIO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 5, 2024 | investorplace.comIOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023March 5, 2024 | globenewswire.comIO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsFebruary 26, 2024 | globenewswire.comIO Biotech to Present at 44th Annual Cowen Health Care ConferenceFebruary 4, 2024 | msn.comWhat's Next for Iovance Biotherapeutics Stock?January 15, 2024 | finance.yahoo.comIO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%January 3, 2024 | seekingalpha.comIO Biotech: A Phase 3 Company Getting No RespectDecember 21, 2023 | finance.yahoo.comIO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialDecember 19, 2023 | finance.yahoo.comWe're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn RateSee More Headlines Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/07/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IOBT CUSIPN/A CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$9.67 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+684.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.31% Return on Assets-62.21% Debt Debt-to-Equity RatioN/A Current Ratio11.24 Quick Ratio11.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book0.61Miscellaneous Outstanding Shares65,880,000Free Float64,366,000Market Cap$81.23 million OptionableNot Optionable Beta0.46 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Mai-Britt Zocca Ph.D. (Age 56)Founder, President, CEO, Principal Financial Officer & Director Comp: $892.24kMr. Devin Whittemore Smith (Age 56)Secretary, General Counsel & Chief Compliance Officer Comp: $621.8kDr. Qasim Iftikhar Ahmad M.D. (Age 53)Chief Medical Officer Comp: $503.28kProf. Inge Marie Svane M.D.Ph.D., Founder & Clinical AdvisorProf. Mads Hald Andersen M.D.Ph.D., Founder & Scientific AdvisorAnders LjungqvistFounderProf. Per Thor StratenFounderMs. Amy B. Sullivan M.B.A. (Age 53)Chief Financial Officer Comp: $391.24kMr. Eric Faulkner M.B.A.Chief Technical OfficerMr. Daniel G. Mannix Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsDURECTNASDAQ:DRRXaTyr PharmaNASDAQ:LIFENanobiotixNASDAQ:NBTXUroGen PharmaNASDAQ:URGNAlto NeuroscienceNYSE:ANROView All CompetitorsInsidersHoldings A/S NovoSold 658,809 sharesTotal: $803,746.98 ($1.22/share)Holdings A/S NovoSold 658,809 sharesTotal: $988,213.50 ($1.50/share)Brian BurkavageBought 5,000 shares on 11/21/2023Total: $4,950.00 ($0.99/share)Vivo Capital Ix, LlcBought 3,157,894 shares on 8/9/2023Total: $6.00 M ($1.90/share)View All Insider Transactions IOBT Stock Analysis - Frequently Asked Questions Should I buy or sell IO Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOBT shares. View IOBT analyst ratings or view top-rated stocks. What is IO Biotech's stock price target for 2024? 3 Wall Street research analysts have issued 1-year target prices for IO Biotech's stock. Their IOBT share price targets range from $7.00 to $12.00. On average, they predict the company's stock price to reach $9.67 in the next twelve months. This suggests a possible upside of 684.0% from the stock's current price. View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts. How have IOBT shares performed in 2024? IO Biotech's stock was trading at $1.88 on January 1st, 2024. Since then, IOBT shares have decreased by 34.4% and is now trading at $1.2330. View the best growth stocks for 2024 here. When is IO Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our IOBT earnings forecast. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.07. When did IO Biotech IPO? IO Biotech (IOBT) raised $111 million in an initial public offering on Friday, November 5th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share. How do I buy shares of IO Biotech? Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOBT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.